Cross-Border Medical Innovation: Singaporean Patient Confronts Multiple Myeloma in China – A Decisive Journey with CAR-T Therapy
Cross-Border Medical Innovation: Singaporean Patient Confronts Multiple Myeloma in China – A Decisive Journey with CAR-T Therapy
Multiple Myeloma
Singaporean patient, Teresa has been battling multiple myeloma for nearly three years. Despite undergoing various conventional treatments including multi-drug therapy, radiation, and chemotherapy, her condition relapsed with extramedullary plasmacytomas affecting her brain, liver, and multiple bones. Recently, after an online consultation with Dr. Vicky Lee and her team at Shanghai Jiahui International Hospital, she made a significant decision: to undergo FUCASO CAR-T therapy in China.
China not only possesses global-leading clinical experience in CAR-T therapy but also offers high-quality commercialized CAR-T products at a competitive price in the global market. Currently, there is an ample supply of these CAR-T products available in China, which is crucial for patients racing against time. Furthermore, the convenience of a single infusion has attracted international attention.
At Shanghai Jiahui International Hospital, an experienced team of hematologic oncology specialists will tailor a personalized treatment plan for Teresa, providing comprehensive and refined diagnostic and therapeutic services. As a pioneer in CAR-T therapy, Jiahui Hospital is about to bring new hope to Ms. Teresa.
We will continue to monitor Teresa’s treatment progress and provide updates.
#CART #CARTTherapy #HopeReborn #FUCASOApproval #Equecel #MultipleMyeloma #JiahuiHospital #Shanghai #Immunotherapy #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART